Knopp’s oral asthma drug hits primary endpoint in phase 2

A phase 2 clinical trial of Knopp Biosciences’ dexpramipexole in patients with moderate-to-severe eosinophilic asthma has met its primary endpoint. Knopp said the data support further development of a drug it is pitching as an oral alternative to antibodies such as Regeneron and Sanofi’s Dupixent.